10 January 2012 - Merck Serono, a unit of Germany's Merck KGaA (ETR:MRK), said on Tuesday that it had enrolled the first patient in the validation study for the first quality-of-life questionnaire specific to phenylketonuria (PKU-QOL questionnaire).

The validation study is the last sta...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up